Non-impactor-Based Methods for Sizing of Aerosols Emitted from Orally Inhaled and Nasal Drug Products (OINDPs)

被引:22
作者
Mitchell, Jolyon [2 ]
Bauer, Richard [3 ]
Lyapustina, Svetlana [1 ]
Tougas, Terrence [4 ]
Glaab, Volker [5 ]
机构
[1] Drinker Biddle & Reath LLP, Pharmaceut Practice Grp, Washington, DC USA
[2] Trudell Med Int, London, ON, Canada
[3] Mannkind Corp, Aerosol Anal, Danbury, CT USA
[4] Boehringer Ingelheim GmbH & Co KG, Analyt Dev, Ridgefield, CT USA
[5] Boehringer Ingelheim GmbH & Co KG, Resp Drug Delivery, Ingelheim, Germany
关键词
aerosol; efficient data analysis; measurement techniques; size distribution; spray; ANDERSEN CASCADE IMPACTOR; PARTICLE-SIZE DISTRIBUTION; DRY POWDER FORMULATION; METERED-DOSE INHALERS; LASER DIFFRACTION; NONSPHERICAL PARTICLES; OPTICAL MEASUREMENT; INLET EXTENSIONS; DROPLET AEROSOLS; SCATTERED-LIGHT;
D O I
10.1208/s12249-011-9662-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this article is to review non-impactor-based methods for measuring particle size distributions of orally inhaled and nasal pharmaceutical aerosols. The assessment of the size distributions of sprays and aerosols from orally inhaled and nasal drug products by methods not involving multi-stage cascade impaction may offer significant potential advantages in terms of labor savings and reducing the risk for operator-related errors associated with complex-to-undertake impactor-based methods. Indeed, in the case of nasal spray products, cascade impaction is inappropriate and alternative, and preferably non-invasive methods must be sought that minimize size-related bias associated with the measurement process for these relatively large droplets. This review highlights the options that are available to those involved with product quality assessments, providing guidance on relative strengths and weaknesses, as well as highlighting precautions that should be observed to minimize bias. The advent of Raman chemical imaging, which enables an estimate to be made of the proportion of each particle comprising active pharmaceutical ingredient(s) (APIs), necessitates a re-think about the value of classical microscopy image analysis as now being capable of providing API-relevant information from collected aerosols and sprays.
引用
收藏
页码:965 / 988
页数:24
相关论文
共 96 条
[21]  
DEBOER AH, 2000, RESP DRUG DELIVERY, V7, P585
[22]   Raman chemical imaging for ingredient-specific particle size characterization of aqueous suspension nasal spray formulations: A progress report [J].
Doub, William H. ;
Adams, Wallace P. ;
Spencer, John A. ;
Buhse, Lucinda F. ;
Nelson, Matthew P. ;
Treado, Patrick J. .
PHARMACEUTICAL RESEARCH, 2007, 24 (05) :934-945
[23]   An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques [J].
Dunbar, CA ;
Watkins, AP ;
Miller, JF .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1997, 10 (04) :351-368
[24]  
EMA, 2006, GUID PHARM QUAL INH
[25]   Particle size analysis: A comparison of various methods II [J].
Etzler, FM ;
Deanne, R .
PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION, 1997, 14 (06) :278-282
[26]  
European Directorate for the Quality of Medicines (EDQM), 2006, PHARMEUROPA, V18, P280
[27]   MEASUREMENT OF PARTICLE-SIZE, NUMBER DENSITY, AND VELOCITY USING A LASER INTERFEROMETER [J].
FARMER, WM .
APPLIED OPTICS, 1972, 11 (11) :2603-&
[28]  
FDA, 2006, GUID IND QUAL SYST A, P32
[29]  
FUHRMAN M, 2010, Patent No. 12684495
[30]  
GEBHART J, 2001, AEROSOL MEASUREMENT, P313